Literature DB >> 18924021

Percutaneous closure of perimembranous ventricular septal defects with Amplatzer occluders--a single centre experience.

Małgorzata Szkutnik1, Jacek Kusa, Jacek Białkowski.   

Abstract

BACKGROUND: Perimembranous ventricular septal defect (VSD) is the most common congenital heart defect. Percutaneous transcatheter closure of VSD is one of the greatest challenges in interventional cardiology. AIM: Presentation of our experience in transcatheter closure of perimembranous VSD.
METHODS: Eighteen patients were treated. Nine patients (group I) had VSD closed with implant Amplatzer Perimembranous VSD Occluder (PMVSDO) whereas the other nine had VSD closed with Muscular VSD Occluder (MVSDO). In the second group the presence of at least 4 mm rim from aortic valve was mandatory to undergo the procedure. Average patients age was 17.1 (3.2-40) years, defect diameter--4.7 (4-8) mm and Qp/Qs ratio--1.84 (1.5-4.6). Perimembranous interventricular septum aneurysm was noted in 5 cases. Only patients who had hemodynamically important defect (Qp/Qs ratio >1.5) were selected for interventional VSD closure. Patients with subarterial VSDs, pulmonary hypertension or/and aortic regurgitation were excluded. Ventricular septal defect closure was performed with standard techniques.
RESULTS: Procedures were completed successfully in 16 of 18 patients. There was no early or late implant embolisation. After the procedure in every case complete closure or important reduction of the shunt was observed. In the group I there was a trend towards more frequent occurrence of rhythm disturbances (p=0,08), including two cases with severe arrhythmias occurring during VSD closure requiring abandoning of procedure. In other 2 cases (patients age 12 and 14 years) in the second week after PMVSDO placement complete atrio-ventricular block occurred. In one patient sinus rhythm was restored after steroid treatment whereas another patient required pacemaker implantation. In group II mild nonprogressive tricuspid regurgitation was noted in 3 patients.
CONCLUSIONS: Percutaneous perimembranous VSD closure is an interesting alternative to surgical treatment. In selected cases closure of the defect with muscular VSD implant is effective and safe.

Entities:  

Mesh:

Year:  2008        PMID: 18924021

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  5 in total

1.  Efficacy and Safety of Using Amplatzer Ductal Occluder for Transcatheter Closure of Perimembranous Ventricular Septal Defect in Pediatrics.

Authors:  Mehdi Ghaderian; Mahmood Merajie; Hodjjat Mortezaeian; Moghadam Aarabi; Yoosef Mohammad; Akbar Shah Mohammadi
Journal:  Iran J Pediatr       Date:  2015-04-18       Impact factor: 0.364

2.  Directly ventricular septal defect closure without using arteriovenous wire loop: Our adult case series using transarterial retrograde approach.

Authors:  Nihat Pekel; Ertuğrul Ercan; Mehmet Emre Özpelit; Ferhat Özyurtlu; Akar Yılmaz; Caner Topaloğlu; Serkan Saygı; Serkan Yakan; İstemihan Tengiz
Journal:  Anatol J Cardiol       Date:  2017-02-21       Impact factor: 1.596

3.  Percutaneous closure of perimembranous ventricular septal defect using patent ductus arteriosus occluders.

Authors:  Hieu Lan Nguyen; Quang Tan Phan; Dung Duc Doan; Linh Huynh Dinh; Hieu Ba Tran; Saima Sharmin; Julian Johny Thottian; Hoyoun Won; Wang Soo Lee; Seung Yong Shin; Truong Quang Nguyen; Sang Wook Kim
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

4.  Simultaneous transcatheter closure of ventricular septal defect and pulmonary valvuloplasty.

Authors:  Mostafa Behjati Ardakani; Mahdi Haddadzadeh; Shahrokh Rajaei
Journal:  Iran J Pediatr       Date:  2012-12       Impact factor: 0.364

5.  Short- and Long-term Outcome After Interventional VSD Closure: A Single-Center Experience in Pediatric and Adult Patients.

Authors:  F Berger; S Schubert; M Bergmann; C P Germann; J Nordmeyer; B Peters
Journal:  Pediatr Cardiol       Date:  2020-10-03       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.